Explore how INB.bio scales in emerging markets with local teams, 100+ products, and full-cycle operations beyond saturated regions. Over the past six years, the company has developed local teams, ...

Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc. (NASDAQ:INAB) reported 2024 financial ...

BERLIN, March 22, 2026 (GLOBE NEWSWIRE)-- Global demand for wellness products is climbing steadily, with the industry reaching a record $6.8 trillion and projected to hit $9.8 trillion by 2029, and a ...

IN8bio announces INB-619, a novel γδ T cell therapy platform targeting CD19, showing promise in B cell depletion with reduced side effects. IN8bio, Inc. has announced the launch of its innovative γδ T ...

IN8bio, Inc (NASDAQ:INAB) updates survival data for its INB-100 trial in a February 11 th press release in preparation for ...

INB-200 shows significantly improved progression-free survival in glioblastoma patients, with favorable safety profile and no serious toxicities reported. Repeated doses of INB-200 demonstrated an ...

Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp ...

Indústrias Nucleares do Brasil has signed a contract with Amazônia Azul Technologias de Defesa SA (Amazul) to provide engineering services for the second phase of the uranium enrichment plant at INB's ...

The MarketWatch News Department was not involved in the creation of this content. BERLIN, March 22, 2026 (GLOBE NEWSWIRE) -- Global demand for wellness products is climbing steadily, with the industry ...